10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes

Rhea-AI Filing Summary

10x Genomics, Inc. director and officer Benjamin J. Hindson reported a small share disposition tied to tax obligations. On May 22, 2026, he sold 11,595 shares of Class A Common Stock at $24.4415 per share to cover tax withholding from vesting restricted stock units. Following this transaction, he still directly holds 502,000 shares, indicating the move is a routine, compensation-related tax event rather than a large discretionary sale.

Insider Trade Summary

Net Seller: 11,595 shares ($283,399)

Net Sell 1 txn

Insider Hindson Benjamin J.

Role See Remarks

Sold 11,595 shs ($283K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	11,595	$24.4415	$283K

Holdings After Transaction: Class A Common Stock — 502,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,595 shares Sale price per share: $24.4415 per share Shares held after transaction: 502,000 shares

3 metrics

Shares sold 11,595 shares Class A Common Stock sold on May 22, 2026

Sale price per share $24.4415 per share Average price for the May 22, 2026 sale

Shares held after transaction 502,000 shares Direct Class A Common Stock holdings after sale

Key Terms

restricted stock units, tax withholding obligations, Class A Common Stock, open-market sale

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to cover tax withholding obligations in connection with the vesting"

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/22/2026		S(1)		11,595	D	$24.4415	502,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

Title: President and Chief Scientific Officer

	/s/ Randy Wu, as Attorney-in-Fact for Benjamin J. Hindson	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did 10x Genomics (TXG) report for Benjamin J. Hindson?

10x Genomics reported that Benjamin J. Hindson sold 11,595 shares of Class A Common Stock. The sale occurred on May 22, 2026 at $24.4415 per share and was linked to tax withholding from vested restricted stock units.

Why did Benjamin J. Hindson sell 10x Genomics (TXG) shares in this Form 4?

The shares were sold specifically to cover tax withholding obligations tied to the vesting of restricted stock units. This indicates a compensation-related, mechanistic transaction rather than a discretionary decision to reduce exposure to 10x Genomics stock.

How many 10x Genomics (TXG) shares did Benjamin J. Hindson sell and at what price?

Benjamin J. Hindson sold 11,595 shares of 10x Genomics Class A Common Stock. The shares were sold at an average price of $24.4415 per share, according to the Form 4 transaction details for May 22, 2026.

How many 10x Genomics (TXG) shares does Benjamin J. Hindson hold after this transaction?

After the reported sale, Benjamin J. Hindson directly holds 502,000 shares of 10x Genomics Class A Common Stock. This remaining position shows the tax-related sale was small relative to his overall direct holdings in the company.

Is Benjamin J. Hindson’s 10x Genomics (TXG) share sale considered an open-market sale?

The Form 4 lists the transaction as an open-market sale coded “S,” but the footnote explains it was executed to cover tax withholding from RSU vesting, making it a routine compensation-related disposition rather than a typical discretionary market sale.